Literature DB >> 3512382

Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.

I Hamilton, H J O'Connor, N C Wood, I Bradbury, A T Axon.   

Abstract

Eighty patients with duodenal ulcer were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Ulcers healed in 78% of patients treated with TDB and in 74% treated with cimetidine, supporting previous observations that the efficacy of these two agents is similar. Duodenal ulcer recurred in 43% of patients in the 12 months after treatment with TDB and in 78% of patients treated with cimetidine, with a significantly greater incidence of recurrence 6-12 months after cimetidine treatment. Tripotassium dicitrato bismuthate tablets may be preferable to cimetidine in the initial management of duodenal ulcer, because they offer a smaller likelihood of recurrence in the 12 months after successful treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512382      PMCID: PMC1433172          DOI: 10.1136/gut.27.1.106

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and denol.

Authors:  M G Moshal; M A Gregory; C Pillay; J M Spitaels
Journal:  Scand J Gastroenterol Suppl       Date:  1979

2.  Microbes, peptic ulcer, and relapse rates with different drugs.

Authors:  A J McLean; P M Harrison; L L Ioannides-Demos; A J Byrne; P McCarthy; F J Dudley
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

3.  Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine.

Authors:  G Bianchi Porro; M Lazzaroni; M Petrillo; C De Nicola
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

4.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Comparison of initial healing and recurrence after healing.

Authors:  J Y Kang; D W Piper
Journal:  Digestion       Date:  1982       Impact factor: 3.216

6.  Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer.

Authors:  G Vantrappen; P Rutgeerts; L Broeckaert; J Janssens
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

7.  Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer.

Authors:  I Hamilton; B W Worsley; H J O'Connor; A T Axon
Journal:  Gut       Date:  1983-12       Impact factor: 23.059

8.  Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate.

Authors:  D F Martin; D Hollanders; S J May; M M Ravenscroft; D E Tweedle; J P Miller
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

9.  Antacid/anticholinergic, cimetidine, and placebo in treatment of active peptic ulcers.

Authors:  M Ström; R Gotthard; G Bodemar; A Walan
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

10.  Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study.

Authors:  W L Burland; B W Hawkins; J Beresford
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

  10 in total
  30 in total

Review 1.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 2.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

Review 3.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

5.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

6.  Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?

Authors:  J P Miller; E B Faragher
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

7.  Peptic ulcer disease. Pathophysiology and current medical management.

Authors:  B F Scharschmidt
Journal:  West J Med       Date:  1987-06

8.  Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats.

Authors:  S J Konturek; A Dembinski; Z Warzecha; W Bielanski; T Brzozowski; D Drozdowicz
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

9.  Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate.

Authors:  A Ahmed; P R Salmon; C R Cairns; M Hobsley; J R Hoult
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

10.  High-affinity binding of the basement membrane proteins collagen type IV and laminin to the gastric pathogen Helicobacter pylori.

Authors:  T J Trust; P Doig; L Emödy; Z Kienle; T Wadström; P O'Toole
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.